Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Hubert H FernandezMichael S Okun

Abstract

To determine whether psychiatrically stable patients with a history of drug-induced psychosis could be successfully weaned off their antipsychotic drug, we offered consecutive Parkinson disease (PD) patients on quetiapine or clozapine, who were free of any on-going psychosis, to be slowly weaned off their antipsychotic drug. Before the study was aborted 6 PD patients (mean age, 78 years) with an average antipsychotic exposure of 20 months (5 on quetiapine, 1 on clozapine) were enrolled. After the antipsychotic agent was discontinued, psychosis recurred in 5 of 6 patients. In 3 patients the "rebound psychosis" was worse than the original psychotic episode and required subsequent higher antipsychotic medication doses.

References

Jun 1, 1978·The American Journal of Psychiatry·C MoskovitzH L Klawans
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
Dec 1, 1996·Archives of Neurology·J R Sanchez-RamosG W Paulson
Mar 11, 1999·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezM Rosenfeld
Mar 29, 2000·Brain : a Journal of Neurology·G FénelonM Ziégler
Apr 6, 2000·Neurology·W J WeinerL M Shulman
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezB P Abbott
Sep 20, 2000·Neurology·H H Fernandez
Jun 11, 2003·Neurology·S A FactorUNKNOWN Parkinson Study Group
Jun 20, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hubert H FernandezJoseph H Friedman
Oct 3, 2003·Expert Opinion on Pharmacotherapy·Janet RomrellMichael S Okun

❮ Previous
Next ❯

Citations

Jun 27, 2006·Journal of Neurologic Physical Therapy : JNPT·Lee E Dibble, Mark Lange
Oct 8, 2005·Postgraduate Medical Journal·B R ThanviD P Harsh
Jul 31, 2008·Drugs & Aging·Laura B Zahodne, Hubert H Fernandez
Dec 7, 2007·Expert Review of Neurotherapeutics·Marco OnofrjLaura Bonanni
Mar 22, 2006·Expert Opinion on Investigational Drugs·Kelvin L Chou, Hubert H Fernandez
Jan 15, 2015·Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater·Jacopo Vittoriano BizzarriHans Peter Kapfhammer
Oct 24, 2017·Clinical Neuropharmacology·Joseph BergmanChanoch Miodownik
Feb 3, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Bernard RavinaChristopher Goetz
Mar 5, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Spiridon Papapetropoulos, Deborah C Mash
Mar 20, 2013·Journal of Psychiatric Practice·Rosa Quelhas
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Hubert H FernandezChristopher G Goetz
Apr 15, 2016·British Journal of Clinical Pharmacology·Amy T PageChristopher D Etherton-Beer
Jul 4, 2006·CNS Spectrums·Leora L BorekJoseph H Friedman
Feb 4, 2010·Parkinsonism & Related Disorders·Josè Martin Rabey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved